Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    "Placenta Praevia" | "Anesthetics"

Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03060889
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : February 23, 2017
Sponsor:
Information provided by (Responsible Party):
Ahmed Elsayed Hassan Elbohoty, Ain Shams University

Brief Summary:
Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa

Condition or disease Intervention/treatment Phase
Placenta Previa Drug: Tranexamic acid Phase 3

Detailed Description:
Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa to detect efficacy of Tranexamic acid in decreasing blood loss

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa: A Randomized Controlled Trial
Study Start Date : February 2016
Actual Primary Completion Date : November 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section

Arm Intervention/treatment
Active Comparator: Cases
Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
Drug: Tranexamic acid
10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion

No Intervention: Controls
Control group will not receive Tranexamic acid



Primary Outcome Measures :
  1. intra operative blood loss in ml [ Time Frame: intraoperative during cesarean section ]
    Calculation of blood loss during cesarean section in the two groups to detect efficacy of Tranexamic acid in reducing blood loss



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Term pregnancy (more than 37 weeks of gestation)
  • Diagnosis of placenta previa was confirmed by ultrasound
  • The patient hemoglobin percentage is more than 10 mg/dl

Exclusion Criteria:

  • Invading placenta previa diagnosis was confirmed by Doppler ultrasound studies
  • Emergency lower segment cesarean section
  • Associated medical comorbidities

Layout table for additonal information
Responsible Party: Ahmed Elsayed Hassan Elbohoty, Principal Investigator, Ain Shams University
ClinicalTrials.gov Identifier: NCT03060889     History of Changes
Other Study ID Numbers: AAbdelaziz
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Ahmed Elsayed Hassan Elbohoty, Ain Shams University:
Cesarean section
placenta previa
Tranexamic acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Placenta Previa
Obstetric Labor Complications
Pregnancy Complications
Placenta Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants